ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026
Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practice.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmunocompromised adults hospitalized for coronavirus disease 2019 (COVID-19) remain at high risk for morbidity. Despite remdesivir's approval for treatment of COVID-19, real-world evidence on its early use, particularly in patients infected with evolving Omicron-era subvariants, remains limited. Contemporary evidence is essential to support hospital pharmacy practice and antiviral stewardship.
methodsWe conducted a retrospective cohort study using the Premier Healthcare Database. Adult immunocompromised patients hospitalized for COVID-19 from December 2021 to December 2024 were included. Patients with COVID-19 present-on-admission who received remdesivir within the first 2 hospital days were compared to untreated patients using 1:1 propensity score matching. The outcomes assessed were 14- and 28-day all-cause mortality. Subgroup analyses assessed outcomes stratified by oxygen requirements and specific immunocompromising conditions.
resultsAmong 22,808 matched patients, early remdesivir use was associated with significantly lower 14-day (hazard ratio [HR], 0.75; 95% CI, 0.69-0.82; P < 0.0001) and 28-day mortality (HR, 0.80; 95% CI, 0.74-0.86; P < 0.0001). Mortality reductions were observed across early and later Omicron periods and among patients with or without supplemental oxygen requirements. Subgroup analyses showed similar survival benefit in patients with cancer, including hematologic malignancies, as well as transplant recipients.
conclusionsEarly remdesivir initiation was associated with clinically meaningful and significant survival benefits in immunocompromised patients hospitalized for COVID-19, with these associations persisting in the Omicron subvariant era. These findings highlight the potential benefit of early antiviral treatment in this vulnerable population while underscoring the need for further prospective studies, including randomized controlled trials, to confirm causal effects and refine treatment strategies. Clinical pharmacists have a pivotal role in ensuring institutional protocols remain aligned with current evidence so that eligible high-risk patients consistently receive appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.